ImmunoPrecise Antibodies Ltd. (IPA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol IPA
- Company ImmunoPrecise Antibodies Ltd.
- Price $0.39
- Changes Percentage -5.42
- Change -0.0221
- Day Low $0.37
- Day High $0.41
- Year High $2.6
- Year Low $0.35
- Market Cap $10,772,615
- Price Avg 50 EMA (D) $0.56
- Price Avg 200 EMA (D) $1.06
- Exchange NASDAQ
- Volume 165,320
- Average Volume 516,260
- Open $0.41
- Previous Close $0.41
- EPS -0.76
- PE -0.51
- Earnings Announcement 2024-12-12 12:00:00
- Shares Outstanding $27,915,560
Company brief: IMMUNOPRECISE ANTIBODIES LTD. (IPA )
- Healthcare
- Biotechnology
- Dr. Jennifer Lynne Bath Ph.D.
- https://www.ipatherapeutics.com
- CA
- N/A
- 01-07-2002
- CA45257F2008
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.